Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.
INTRODUCTION: The Lambert Eaton myasthenic syndrome (LEMS) is a paraneoplastic disorder associated with raised serum voltage-gated calcium channel (VGCC) antibodies in patients with small cell lung cancer (SCLC). VGCC can also be found in patients with SCLC and cerebellar ataxia. This was a prospec...
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Journal article |
| 語言: | English |
| 出版: |
2010
|
| _version_ | 1826289171960954880 |
|---|---|
| author | Payne, M Bradbury, P Lang, B Vincent, A Han, C Newsom-Davis, J Talbot, D |
| author_facet | Payne, M Bradbury, P Lang, B Vincent, A Han, C Newsom-Davis, J Talbot, D |
| author_sort | Payne, M |
| collection | OXFORD |
| description | INTRODUCTION: The Lambert Eaton myasthenic syndrome (LEMS) is a paraneoplastic disorder associated with raised serum voltage-gated calcium channel (VGCC) antibodies in patients with small cell lung cancer (SCLC). VGCC can also be found in patients with SCLC and cerebellar ataxia. This was a prospective study to assess the incidence of clinical and subclinical LEMS or other neurologic disease in patients with SCLC. PATIENTS AND METHODS: Sixty-three unselected patients with cytologically or histologically confirmed SCLC consented to participate. Pretreatment assessment included a neurologic symptom questionnaire, examination for physical signs of LEMS or ataxia, measurement of serum titers of antibodies to P/Q-type VGCCs by radioimmunoassay in all patients and electrophysiological examination where appropriate. RESULTS: Neurologic symptoms unrelated to LEMS occurred in 26% of patients. Five patients (8%) had raised serum VGCC antibodies (range, 69-1553 pM/l) diagnostic of LEMS, two (3%) of whom had LEMS on clinical and electrophysiological grounds. Both also had mild cerebellar ataxia. There was no association between serum VGCC antibody titer and survival. CONCLUSION: Routine measurement of VGCC antibodies in patients without clinical LEMS is unlikely to assist either in management of SCLC or in assessment of prognosis. |
| first_indexed | 2024-03-07T02:24:50Z |
| format | Journal article |
| id | oxford-uuid:a53d77e2-2a60-4a7c-ab58-44b3dee989ef |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:24:50Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:a53d77e2-2a60-4a7c-ab58-44b3dee989ef2022-03-27T02:39:05ZProspective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a53d77e2-2a60-4a7c-ab58-44b3dee989efEnglishSymplectic Elements at Oxford2010Payne, MBradbury, PLang, BVincent, AHan, CNewsom-Davis, JTalbot, D INTRODUCTION: The Lambert Eaton myasthenic syndrome (LEMS) is a paraneoplastic disorder associated with raised serum voltage-gated calcium channel (VGCC) antibodies in patients with small cell lung cancer (SCLC). VGCC can also be found in patients with SCLC and cerebellar ataxia. This was a prospective study to assess the incidence of clinical and subclinical LEMS or other neurologic disease in patients with SCLC. PATIENTS AND METHODS: Sixty-three unselected patients with cytologically or histologically confirmed SCLC consented to participate. Pretreatment assessment included a neurologic symptom questionnaire, examination for physical signs of LEMS or ataxia, measurement of serum titers of antibodies to P/Q-type VGCCs by radioimmunoassay in all patients and electrophysiological examination where appropriate. RESULTS: Neurologic symptoms unrelated to LEMS occurred in 26% of patients. Five patients (8%) had raised serum VGCC antibodies (range, 69-1553 pM/l) diagnostic of LEMS, two (3%) of whom had LEMS on clinical and electrophysiological grounds. Both also had mild cerebellar ataxia. There was no association between serum VGCC antibody titer and survival. CONCLUSION: Routine measurement of VGCC antibodies in patients without clinical LEMS is unlikely to assist either in management of SCLC or in assessment of prognosis. |
| spellingShingle | Payne, M Bradbury, P Lang, B Vincent, A Han, C Newsom-Davis, J Talbot, D Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. |
| title | Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. |
| title_full | Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. |
| title_fullStr | Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. |
| title_full_unstemmed | Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. |
| title_short | Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. |
| title_sort | prospective study into the incidence of lambert eaton myasthenic syndrome in small cell lung cancer |
| work_keys_str_mv | AT paynem prospectivestudyintotheincidenceoflamberteatonmyasthenicsyndromeinsmallcelllungcancer AT bradburyp prospectivestudyintotheincidenceoflamberteatonmyasthenicsyndromeinsmallcelllungcancer AT langb prospectivestudyintotheincidenceoflamberteatonmyasthenicsyndromeinsmallcelllungcancer AT vincenta prospectivestudyintotheincidenceoflamberteatonmyasthenicsyndromeinsmallcelllungcancer AT hanc prospectivestudyintotheincidenceoflamberteatonmyasthenicsyndromeinsmallcelllungcancer AT newsomdavisj prospectivestudyintotheincidenceoflamberteatonmyasthenicsyndromeinsmallcelllungcancer AT talbotd prospectivestudyintotheincidenceoflamberteatonmyasthenicsyndromeinsmallcelllungcancer |